On 6 July 2022, Future Health Pharma GmbH applied to Swissmedic for an indication extension for the vaccine from 12-18 years and authorisation for the booster. The Swiss Agency for Therapeutic Products has assessed both applications positively.
Swissmedic authorises indication extension and booster
Swissmedic has reviewed and approved the clinical data submitted for both applications with regard to efficacy, safety and quality. Nuvaxovid, the COVID-19 vaccine from Novavax, is now approved for young people aged 12 and over with immediate effect. It is administered intramuscularly as a series of two doses of 0.5 ml each. It is recommended that the second dose be administered three weeks after the first dose. The vaccine can also be used as a booster following basic vaccination. Nuvaxovid can be administered as a homologous or heterologous booster following basic immunisation for people aged 18 and over.